{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.1","upperLimit":"23.0","value":"11.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"55"}],"units":"Participants"}],"description":"Disseminated recurrence is defined as uninvolved lobe failures and failures beyond the lungs and regional lymph nodes. Time to disseminated recurrence is defined as time from start of treatment to the the date of disseminated recurrence, last known follow-up (censored), or death without disseminated recurrence (competing risk). Rates are estimated using the cumulative incidence method.","dispersionType":"95% Confidence Interval","groups":[{"description":"20 Gy per fraction for 3 fractions over 1.5-2 weeks, for a total of 60 Gy","id":"OG000","title":"Stereotactic Body Radiation Therapy (SBRT)"}],"paramType":"NUMBER","populationDescription":"Eligible patients","reportingStatus":"POSTED","timeFrame":"From the start of treatment to 2 years","title":"Rate of Disseminated Recurrence at 2 Years","type":"SECONDARY","unitOfMeasure":"percentage of participants"}